Pacira BioSciences, Inc.

NASDAQ:PCRX

Drug Manufacturers - Specialty & Generic

Healthcare
$36.48 -0.79%

-$0.18 today

Market cap
$1.46B
Beta
0.29
P/E (TTM)
176.9
EPS (TTM)
$0.13
52W Low $18.80High $27.64

Volume 1.81M

Average 0.57M

PCRX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Pacira BioSciences, Inc.NASDAQ: PCRX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) declines year over year

Q1 FY2026 weighted avg shares (diluted) of 40.91M shares fell 12.1% year over year, behind the -9.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.1% toward the trailing-twelve-month pace of -9.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
40.91M-4.8% QoQ
Last fiscal yearDec 2025
45.04M-2.6% YoY
LTMMar 2026
43.45M-9.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.1%——
1 year-2.6%——
3-year CAGR-1.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
45.04M USD
Year-over-year change
-2.6%
4-year CAGR
-0.3%

Weighted Avg Shares (Diluted) vs competitors

How PCRX compares with its peers on the latest reported figures

  • PCRX's LTM Mar 2026 weighted avg shares (diluted) of 43.45M shares is the 2nd highest of the 4 companies compared; the peer median is 39.57M shares.
  • Its year-over-year change of -9.6% is the lowest of 4, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of -1.1% compares with a peer median of +5.5%.
PCRX Competitors Peer median
Weighted Avg Shares (Diluted) for PCRX and competitors
Company Period LTM YoY 3-year CAGR
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.4M +2.1%-2.9%
PCRXPacira BioSciences, Inc.LTM Mar 202643.45M -9.6%-1.1%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202639.57M +3.1%+5.5%
SCLXScilex Holding CompanyLTM Mar 202610.28M +60.8%+42.2%
LTGOLatigo Biotherapeutics Inc.—— ——
Peer median (excluding PCRX) 39.57M+3.1%+5.5%

Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue541.53M666.82M674.98M700.97M726.41M
Cost of Revenue140.26M199.3M184.67M170.43M149.75M
Gross Profit401.28M467.53M490.31M530.54M576.66M
Gross Margin74.1%70.1%72.6%75.7%79.4%
Research & Development55.55M84.8M76.26M81.58M117.31M
Selling, General & Admin199.35M254.52M269.44M294.1M368.76M
Operating Expenses311.35M407.5M402.63M603.91M543.36M
Depreciation & Amortization28.55M91.5M75.57M78.79M91.02M
EBITDA113.95M140.38M154.59M29.12M122.5M
EBITDA Margin21.0%21.1%22.9%4.2%16.9%
Operating Income89.92M60.02M87.68M(73.37M)33.3M
Operating Margin16.6%9.0%13.0%-10.5%4.6%
Interest Income896K4.54M11.44M19.69M22.73M
Interest Expense29M35.58M17.31M16.57M14.61M
Other Income / Expenses(33.52M)(46.72M)(25.97M)10.27M(16.43M)
Income Before Tax56.4M13.3M61.7M(63.11M)16.87M
Pre-Tax Margin10.4%2.0%9.1%-9.0%2.3%
Income Tax Expense14.42M(2.61M)19.75M36.45M9.84M
Net Income41.98M15.91M41.96M(99.56M)7.03M
Net Margin7.8%2.4%6.2%-14.2%1.0%
EPS (Basic)0.950.350.91(2.15)0.16
EPS (Diluted)0.920.340.89(2.15)0.16
Weighted Avg Shares44.26M45.52M46.22M46.25M44.57M
Weighted Avg Shares (Diluted)45.63M46.54M51.98M46.25M45.04M

Pacira BioSciences, Inc.

NASDAQ:PCRX

Intrinsic Alpha fair value

Locked

Current Price

$36.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.